This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mani, C. Articles by Kupfer, D. Search for Related Content PubMed PubMed Citation Articles by Mani, C. Articles by Kupfer, D.

Cytochrome P-450-mediated Activation and Irreversible Binding of the Antiestrogen Tamoxifen to Proteins in Rat and Human Liver: Possible Involvement of Flavin-containing Monooxygenases in Tamoxifen Activation¹

Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545

Tamoxifen (TXF), a triphenylethylene antiestrogen, is the major therapeutic agent for breast cancer. In rare cases, TXF treatment appears to increase incidence of endometrial cancer. Also in rats, TXF was found to induce hepatocellular carcinoma. Previous studies suggested that metabolism of TXF may contribute to its antiestrogenic and anticancer activity. The current study demonstrates a novel route of TXF metabolism. TXF is metabolized by rat and human liver microsomes into a reactive intermediate (txf*) which binds irreversibly to microsomal proteins. The binding requires NADPH and O₂ and is inhibited by CO, inhibitors of P-450, and antibodies to rat NADPH-P450 reductase, indicating catalysis by P450. Phenobarbital treatment of rats markedly increases binding, suggesting the involvement of induced P450s. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins from incubation of [¹⁴C] TXF with phenobarbital-treated microsomes exhibits a major radiolabeled zone which corresponds to a molecular weight of approximately 54,000, suggesting binding to a P-450. Cysteine and glutathione inhibited the binding of TXF without significantly affecting P-450-mediated metabolism of TXF, possibly by reacting with txf* or by competing for the same binding sites. Exposure of phenobarbital-treated microsomes and control-microsomes to 50°C for 90 s, which inactivates the flavin-containing monooxygenase (FMO), diminished binding and pH 8.6 enhanced binding. Also, alternate FMO substrates inhibited binding. These findings indicate that P-450 and possibly FMO catalyze the reactions leading to the formation of txf*. However, incubations with single-labeled and dual-radiolabeled tamoxifen or with [¹⁴C]TXF-N-oxide demonstrated that monodesmethyl-TXF and TXF-N-oxide, the principal P-450 and FMO-mediated metabolites, respectively, are not on the major route of txf* formation, indicating that txf* could not be an aldehyde derived from tamoxifen nitrone. Thus, though the structure of txf* was not characterized, certain possibilities were excluded. Speculations on the structure of txf* and on its possible pharmacological and toxicological activity are presented.

¹ This work was supported by USPHS Grant ES00834 from the National Institute for Environmental Health Sciences. A preliminary report of this investigation was presented (45).

² To whom requests for reprints should be addressed.

Received 5/28/91. Accepted 9/10/91.

This article has been cited by other articles:

				P. Parte and D. Kupfer OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN Drug Metab. Dispos., October 1, 2005; 33(10): 1446 - 1452. [Abstract] [Full Text] [PDF]

				J. M. Reid, D. L. Walker, J. K. Miller, L. M. Benson, A. J. Tomlinson, S. Naylor, A. L. Blajeski, P. M. LoRusso, and M. M. Ames The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes Clin. Cancer Res., February 15, 2004; 10(4): 1471 - 1480. [Abstract] [Full Text] [PDF]

				E. A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R. C. Garner, D. J. Boocock, E. Mattock, D. W. Pring, K. Dingley, K. W. Turteltaub, et al. Tamoxifen DNA Damage Detected in Human Endometrium Using Accelerator Mass Spectrometry Cancer Res., December 1, 2003; 63(23): 8461 - 8465. [Abstract] [Full Text] [PDF]

				C. Sridar, U. M. Kent, L. M. Notley, E. M. J. Gillam, and P. F. Hollenberg Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6 J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 945 - 952. [Abstract] [Full Text] [PDF]

				P. W. Fan and J. L. Bolton Bioactivation of Tamoxifen to Metabolite E Quinone Methide: Reaction with Glutathione and DNA Drug Metab. Dispos., June 1, 2001; 29(6): 891 - 896. [Abstract] [Full Text]

				A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al. Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744. [Abstract] [Full Text] [PDF]

				S. Katchamart, D. M. Stresser, S. S. Dehal, D. Kupfer, and D. E. Williams Concurrent Flavin-Containing Monooxygenase Down-Regulation and Cytochrome P-450 Induction by Dietary Indoles in Rat: Implications for Drug-Drug Interaction Drug Metab. Dispos., August 1, 2000; 28(8): 930 - 936. [Abstract] [Full Text]

				W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]

				M. Kawai, S. M. Bandiera, T. K. H. Chang, F. M. Poulet, P. M. Vancutsem, and G. D. Bellward Modulation of Hepatic CYP2A1, CYP2C11, and CYP3A9 Expression in Adult Rats by Neonatal Administration of Tamoxifen Drug Metab. Dispos., December 1, 1999; 27(12): 1392 - 1398. [Abstract] [Full Text]

				K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016. [Abstract] [Full Text] [PDF]

				S. S. Dehal and D. Kupfer Cytochrome P-450 3A and 2D6 Catalyze Ortho Hydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (Droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins Drug Metab. Dispos., June 1, 1999; 27(6): 681 - 688. [Abstract] [Full Text]

				S. S. Dehal, A. M. H. Brodie, and D. Kupfer The Aromatase Inactivator 4-Hydroxyandrostenedione (4-OH-A) Inhibits Tamoxifen Metabolism by Rat Hepatic Cytochrome P-450 3A: Potential for Drug-Drug Interaction of Tamoxifen and 4-OH-A in Combined Anti-Breast Cancer Therapy Drug Metab. Dispos., March 1, 1999; 27(3): 389 - 394. [Abstract] [Full Text]

				D. J. Boocock, J. L. Maggs, I. N.H. White, and B. K. Park {alpha}-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro Carcinogenesis, January 1, 1999; 20(1): 153 - 160. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				K. Monostory, K. Jemnitz, L. Vereczkey, and G. Czira Species Differences in Metabolism of Panomifene, an Analogue of Tamoxifen Drug Metab. Dispos., December 1, 1997; 25(12): 1370 - 1378. [Abstract] [Full Text]

				M. M. Miller, R. A. James, J. K. Richer, D. F. Gordon, W. M. Wood, and K. B. Horwitz Progesterone Regulated Expression of Flavin-Containing Monooxygenase 5 by the B-Isoform of Progesterone Receptors: Implications for Tamoxifen Carcinogenicity J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2956 - 2961. [Abstract] [Full Text] [PDF]

				U. Gundimeda, Z.-H. Chen, and R. Gopalakrishna Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells J. Biol. Chem., June 7, 1996; 271(23): 13504 - 13514. [Abstract] [Full Text] [PDF]